Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises

Zacks
Zacks에서 열기
Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises

Charles River Laboratories International, Inc. CRL reported third-quarter 2026 adjusted earnings per share (EPS) of $3.09, up 27.2% year over year. The metric beat the Zacks Consensus Estimate by 3.69%.

On a GAAP basis, the company reported earnings of $6.86 per share compared with $1.10 in the year-ago quarter.

Revenues totaled $982.7 million, down 2.2% year over year (up 4.7% organically). The figure topped the Zacks Consensus Estimate by 2.71%.

Following the announcement, CRL shares climbed 2.9% in the pre-market session today.

Charles River's Q3 Segmental Performance in Detail

The company reports under three segments: Research Models and Services (“RMS”), Discovery and Safety Assessment (“DSA”) and Manufacturing Solutions.

RMS' revenues totaled $207.5 million, down 2.8% year over year (down 0.6% organically). The organic decline primarily reflected lower revenues for small research models in North America and large research models. Higher revenues for small research models in China and research model services, particularly Insourcing Solutions, provided some offset.

Charles River Laboratories International, Inc. Price, Consensus and EPS Surprise

Charles River Laboratories International, Inc. Price, Consensus and EPS Surprise

Charles River Laboratories International, Inc. price-consensus-eps-surprise-chart | Charles River Laboratories International, Inc. Quote

DSA's revenues amounted to $596.3 million, down 0.7% year over year (up 5.9% organically). The reported decrease primarily reflected the divestiture of certain European Discovery Services sites. Organic growth was mainly driven by higher study volumes for regulated safety assessment services.

Manufacturing Solutions' revenues totaled $178.9 million, down 6.2% year over year (up 7.4% organically). The reported decline reflected the CDMO divestiture, while strong demand across the Biologics Testing Solutions and Microbial Solutions businesses supported organic growth.

CRL’s Margin Performance

The gross profit in the reported quarter was $357.9 million, up 5.6% from the prior-year quarter’s level. The gross margin of 36.4% expanded 270 basis points (bps) year over year.

Selling, general & administrative expenses dropped 20.8% year over year to $140.6 million. The adjusted operating profit totaled $225.8 million, up 14.2% from the prior-year quarter’s level. The adjusted operating margin expanded 330 bps to 23.0%.

Charles River's Liquidity Position

Charles River exited the third quarter with cash and cash equivalents of $200.4 million compared with $213.8 million at the end of 2025.

During the first nine months of 2026, cumulative net cash provided by operating activities totaled $474.9 million compared with $590.1 million a year ago. Capital expenditures increased to $133.8 million from $130.2 million.

The company spent $324.1 million on treasury stock purchases during the nine-month period. Long-term debt, net of finance leases, stood at $2.44 billion at the quarter's end compared with $2.14 billion at the end of 2025.

CRL Raises 2026 Guidance 

Charles River raised its full-year 2026 outlook for revenues and adjusted earnings, primarily reflecting better-than-expected third-quarter performance in DSA and a lower tax rate.

Reported revenues are now expected to decline 1.5-2% compared with the previous forecast of a 2.5-3.5% drop. Organic revenue growth is expected to be at least 1.5%, up from the earlier projection of 0-1% growth. The Zacks Consensus Estimate for 2026 revenues stands at $3.91 billion at present.

Adjusted EPS is now projected between $11.35 and $11.55 compared with the previous guidance of $11.15-$11.45. The Zacks Consensus Estimate for 2026 adjusted EPS is pegged at $11.35.

Charles River's Strategic and Operational Updates

Charles River unveiled its Pathway to Purpose strategic vision and Create the Future initiative on its 2026 Investor Day. These initiatives aim to strengthen operational efficiency, scientific leadership and long-term value creation.

The company also advanced manufacturing modernization through its Endosafe Cartridge Technology Automated Manufacturing Suite. Its partnership with Autolomous introduced Apollo Orchestrate, designed to digitize laboratory workflows and improve operational efficiency.

Charles River strengthened its scientific capabilities through an FDA collaboration to validate preclinical screening tools and expanded its Alternative Methods Advancement Project initiative with new cell banking capabilities and virtual control group methodologies.

Our Take on CRL Stock

Charles River exited the third quarter of 2026 with earnings and revenues beating estimates. The company's return to organic revenue growth for the second consecutive quarter, along with strong margin expansion, is encouraging. Segment-wise, solid organic revenue growth in DSA and Manufacturing Solutions more than offset the modest decline in RMS. Higher study volumes for regulated safety assessment services and strong demand across the Manufacturing businesses supported the performance.

The expansion of both gross and adjusted operating margins is encouraging, reflecting improved operating efficiency. The upward revision to the company's 2026 revenue and earnings outlook also raises optimism. However, the year-over-year decline in reported revenues, continued weakness in RMS and lower operating cash flow remain concerning.

CRL’s Zacks Rank & Key Picks

Charles River currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Bausch + Lomb BLCO, Medpace MEDP and Intuitive Surgical ISRG

Bausch + Lomb, sporting a Zacks Rank #1 (Strong Buy) at present, posted third-quarter 2026 adjusted EPS of 34 cents, exceeding the Zacks Consensus Estimate by 61.91%. Revenues of $1.28 billion topped the Zacks Consensus Estimate by 0.14%. You can see the complete list of today’s Zacks #1 Rank stocks here.

BLCO has an estimated long-term earnings growth rate of 40.1% compared with the industry’s 13.5% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 21.67%.

Medpace, carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $4.84, which surpassed the Zacks Consensus Estimate by 8.76%. Revenues of $716 million beat the Zacks Consensus Estimate by 1.02%.

MEDP has an estimated long-term earnings growth rate of 14.3% compared with the industry’s 13.2% growth. The company outperformed earnings estimates in each of the trailing four quarters, the average surprise being 9.77%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, posted third-quarter 2026 adjusted EPS of $3.00, exceeding the Zacks Consensus Estimate by 14.94%. Revenues of $3.05 billion topped the Zacks Consensus Estimate by 5.84%.

ISRG has an earnings yield of 2.5% against the industry’s negative 2.1% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 15.12%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Charles River Laboratories International, Inc. (CRL): Free Stock Analysis Report
 
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
 
Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report
 
Bausch + Lomb Corporation (BLCO): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research